FDA accepted United Therapeutics' sNDA for inhaled treprostinil in IPF. Here's what it could mean for patient access, ...

Weighted average monthly Medicare Advantage (MA) premiums are projected to fall 16.5% in 2027, while average premiums for ...

AASM urges CMS to reject proposed 2027 Medicare conversion factor cuts of 1.19% to 1.68% and revise sleep testing and remote ...

A rare case of soft-tissue sarcoma spreading to the heart shows how multimodal imaging guided diagnosis and care in a 36-year ...

At the Community Oncology Alliance Payer Exchange & Innovation Summit in September, a panel of statistical experts posed a ...

CAR T-cell therapy must be treated as a complete "vein-to-vein" episode, with community practices needing to take control of cases for a period of time.

Any weekend catch-up sleep was independently associated with lower OAB odds (adjusted OR 0.79; 95% CI 0.67–0.93) after ...

Open-source oncology tools span patient-facing trackers and explainers, genomics-to-therapy ranking systems, and LLMs ...

Specialty pharmacy workflows—access, education, interaction checks, toxicity management—mitigate BTK antiplatelet risks and ...

Weekly cataplexy rates fell ~79%–89% with oveporexton versus ~28%–39% with placebo, increasing cataplexy-free days from 0 to ~3.8–5.1 weekly. Treatment-emergent adverse events were common (86%–89% vs ...

In "Evaluating Suspected LEMS: Differential Diagnosis and Palliative Care's Role," the panel examines how to evaluate a patient once LEMS enters the differential.

Dr. Patel defines LEMS as a neuromuscular disorder in which the synapses between nerve and muscle stop firing properly.